PULMONARY HTN-GROUP 1 TX

SUMMARY

MEDICATIONS
1. Pulmonary specific vasodilator therapies
2. Initial treatment strategy tailored to disease severity
3. Combination oral therapy (endothelin receptor antagonist and PDE5 inhibitor)
4. Intravenous epoprostenol efficacious in patients with advanced disease with high initial mortality risk (high risk patients)

GENERAL ADVICE
1. Avoid pregnancy
2. Oxygen therapy if required
3. Exercise programme rehab in deconditioned patients who are stable on therapy

Reference(s)

Wilkinson, I., Furmedge, D. and Sinharay, R. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. Get it on Amazon.
Feather, A., Randall, D. and Waterhouse, M. (2020). Kumar And Clark’s Clinical Medicine. 10th ed. S.L.: Elsevier Health Sciences. Get it on Amazon.
Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy.
Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021].